Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank50
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-1.66
↑ 50% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive declineElevated
Average
-3.32
Historical baseline
PeriodValueYoY Change
2024-1.66-43.9%
2023-1.15+83.8%
2022-7.14-